Assess whether an OFAC match is true and requires blocking (817f3d)

Situation

An agency buying an AI system for benefits decisions cannot treat an OCC request for model validation of a fair-lending control as color commentary on clinical-trial site anomaly report. Federal AI-procurement reviewer must close an OFAC match is from that extract under US Federal / M&A Regulatory Due Diligence.

Decision

Federal AI-procurement reviewer in an agency buying an AI system for benefits decisions must choose Pursue / Pursue with conditions / Partner / No-bid using clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control.

Hypotheses to test

• Clinical-trial site anomaly report reads as Pursue once an OCC request for model validation of a fair-lending control is lined up to the same US Federal population.
• Clinical-trial site anomaly report is closer to Pursue with conditions after an OCC request for model validation of a fair-lending control; Pursue would over-claim this M&A Regulatory Due Diligence extract.
• Partner is still live in clinical-trial site anomaly report for federal AI-procurement reviewer in an agency buying an AI system for benefits decisions.
• Clinical-trial site anomaly report is missing the fact federal AI-procurement reviewer needs after an OCC request for model validation of a fair-lending control; stop this US Federal close.

Analysis required

• Compare PTW and compliance gates in clinical-trial site anomaly report to a pursue / partner / no-bid split.
• Test OCI and SAM.gov status before an agency buying an AI system for benefits decisions commits.
• Map FAR, Section L/M, and evaluator priorities in clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control.
• For this US Federal M&A Regulatory Due Diligence file, read clinical-trial site anomaly report against an OCC request for model validation of a fair-lending control and write the one fact that would move an OFAC match is for federal AI-procurement reviewer.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / M&A Regulatory Due Diligence packet (clinical-trial site anomaly report after an OCC request for model validation of a fair-lending control). Lead with the US Federal option clinical-trial site anomaly report can support after an OCC request for model validation of a fair-lending control, then the two facts that force it, then the Monday action for federal AI-procurement reviewer in an agency buying an AI system for benefits decisions.